Clinical Trials
3 trialsNCT05823480 2024-09-19
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
City of Hope Medical Center
Phase 1 Withdrawn
NCT05367401 2024-04-11
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Novartis
Phase 1/2 Withdrawn
NCT02678338 2019-02-21
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
Gilead Sciences
Phase 1 Completed